GTGraham R. Taylor

Graham R. Taylor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Graham R. Taylor has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander F. Markham

    Department of Oncology; Leeds Teaching Hospitals NHS Trust; Leeds; West Yorkshire; UK

    2 shared publications
  • Joanne E. Morgan

    Leeds Institute of Molecular Medicine; Leeds University; Leeds; UK

    2 shared publications
  • A. Tsika

    Leeds Institute of Molecular Medicine, Leeds, UK

    1 shared publication
  • Bruce Hayward

    University of Leeds Institute of Molecular Medicine, Wellcome Trust Brenner Building, St. James's University Hospital, Leeds, United Kingdom

    1 shared publication
  • Carol E. Chu

    Department of Clinical Genetics, Leeds Teaching Hospitals Trust St. James's University Hospital, Leeds, United Kingdom

    1 shared publication
  • Chris J. Mattocks

    National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, United Kingdom

    1 shared publication

Latest Publications

  • Mutation Detection by Clonal Sequencing of PCR Amplicons and Grouped Read Typing is Applicable to Clinical Diagnostics

    by Philip A. Chambers, Lucy F. Stead, Joanne E. Morgan, Ian M. Carr, Kate M. Sutton, Christopher M. Watson, Victoria Crowe, Helen Dickinson, Paul Roberts, Clive Mulatero, et al.

    We describe a sensitive technique for mutation detection using clonal sequencing. We analyzed DNA extracted from 13 cancer cell lines and 35 tumor samples and applied a novel approach to identify disease‐associated somatic mutations. By matching reads against an index of known variants, noise can be dramatically reduced, enabling the detection and quantification of those variants, even when they are present at less than 1% of the total sequenced population; this is comparable to, or better than, current diagnostic methods. Following the identification or exclusion of known variants, unmatched reads are grouped for BLAST searching to identify novel variants or contaminants. Known variants, novel variants, and contaminants were readily identified in tumor tissue using this approach. Our approach also enables an estimation of the per‐base sequencing error rate, providing a confidence threshold for interpretation of the results in the clinic. This novel approach has immediate applicability to clinical testing for disease‐associated genetic variants.


  • Molecular karyotyping using massively parallel sequencing - a next generation approach to prenatal diagnosis?

    by K. E. Cohen, J. Morgan, H. Wood, A. Tsika, S. Berri, G. C. Mason, E. Sheridan, G. R. Taylor

    Underlying chromosomal copy number variation is responsible for 10–15% of fetal structural abnormalities, but even in the presence of a normal karyotype neonatal outcome can be poor. Current whole genome prenatal analysis is limited to G-banded karyotyping. Prenatal microarrays have yet to be fully established, but detection rates of up to 5.8% are reported.1 Potential disadvantages of arrays include the reliance on nucleic acid hybridisation, where fluctuations may increase experimental noise and reduce reproducibility.2 Prenatal material is commonly of low quantity and quality, characteristics which inhibit performance of microarrays. We have developed an alternative method of copy number diagnosis using Next Generation Sequencing (CNV-Seq). Massively-parallel sequencing of test and control individuals is performed using the Illumina Genome Analyser platform. Millions of genomic reads are aligned to the reference sequence and analysed using custom-designed segmentation algorithms. Comparison with similarly-segmented normal controls is then performed for accurate variant detection. Analysis of platform performance showed 100% detection rate in 10 prenatal samples with known chromosomal abnormalities ranging in size from submicroscopic microdeletion syndromes to aneuploidy. Multiplexing of up to 15 samples is possible for cost benefits without loss of sensitivity. Depth of coverage required is fractions of that reported previously.3 Comparison with array CGH data supports the hypothesis that CNV-Seq offers advantages over both conventional karyotyping and DNA microarrays. We suggest that this approach is unique in its potential to offer a single platform solution for genetic analysis, allowing detection of a range of abnormalities from single point mutations to balanced rearrangements and aneuploidy.


  • Genetic diagnosis of familial breast cancer using clonal sequencing

    by Joanne E. Morgan, Ian M. Carr, Eamonn Sheridan, Carol E. Chu, Bruce Hayward, Nick Camm, Helen A. Lindsay, Chris J. Mattocks, Alexander F. Markham, David T. Bonthron, et al.

    Using conventional Sanger sequencing as a reference standard, we compared the sensitivity, specificity, and capacity of the Illumina GA II platform for the detection of TP53, BRCA1, and BRCA2 mutations in established tumor cell lines and DNA from patients with germline mutations. A total of 656 coding variants were identified in four cell lines and 65 patient DNAs. All of the known pathogenic mutations (including point mutations and insertions/deletions of up to 16 nucleotides) were identified, using a combination of the Illumina data analysis pipeline with custom and commercial sequence alignment software. In our configuration, clonal sequencing outperforms current diagnostic methods, providing a reduction in analysis times and in reagent costs compared with conventional sequencing. These improvements open the possibility of BRCA1/2 testing for a wider spectrum of at-risk women, and will allow the genetic classification of tumors prior to the use of novel PARP inhibitors to treat BRCA-deficient breast cancers. Hum Mutat 31:1–8, 2010.


    • 1 February 2007
      • Vol. 120  (6) , 910

    Gene symbol: BRCA1.

    by G R Taylor, S Bibi, R F Charlton